RxDoctor Payments Data

Leon Charkoudian, MD

Ophthalmology · Wilmington, NCNPI 1194874131

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,231 of the $2,974 with a category attached, or 75.0%. 16 manufacturers reported payments, led by Notal Vision, Inc. at 26.1% of the total. Reporting peaked in 2022 at $1,259 and has fallen 64.8% since, to $443 in 2025.

$2,974in general payments, 2019–2025

Across 105 payments — averaging $28.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Notal Vision, Inc.$775
  • Genentech USA, Inc.$577
  • AbbVie$346
  • Regeneron Healthcare Solutions, Inc.$333
  • Bausch & Lomb Americas Inc.$176
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$162
  • plus $605 from 10 others
$108,717in research payments, 2019–2025

Across 251 payments — averaging $433.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$100K
  • Notal Vision, Inc.$9K

What the payments were for

  • Speaking & faculty fees$74325%
  • Food & beverage$2,23175%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,974 in reported general payments places this provider in the 70th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$3,576,218
Medicare patients
1,010
Services billed
73,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate284$13,013
Difluprednate26$2,676
Ketorolac Tromethamine103$2,062
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat107$1,589
Timolol Maleate86$1,154
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim70$458
Dorzolamide Hcl23$447
Brimonidine Tartrate57$287
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$91

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →